Cancer Therapy : Preclinical Tipping the Noxa / Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

@inproceedings{Tromp2012CancerT,
  title={Cancer Therapy : Preclinical Tipping the Noxa / Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia},
  author={Jacqueline M. Tromp and Christian R. Geest and Esther C W Breij and Judith A. Elias and Jacoline van Laar and Dieuwertje M P Luijks and Arnon P Kater and T. Beaumont and Marinus H. J. van Oers and Eric Eldering},
  year={2012}
}
Purpose: Chronic lymphocytic leukemia (CLL) cells in lymph nodes (LN), from which relapses are postulated to originate, display an antiapoptotic profile in contrast to CLL cells from peripheral blood (PB). The BH3 mimetic ABT-737 antagonizes the antiapoptotic proteins Bcl-XL and Bcl-2 but not Mcl-1 or Bfl-1. Previously, it was shown that CD40-stimulated CLL cells were resistant to ABT-737. We aimed to define which antiapoptotic proteins determine resistance to ABT-737 in CLL and whether… CONTINUE READING